Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H24Cl2N2O |
Molecular Weight | 355.302 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN([C@@H]1CCCC[C@H]1N2CCCC2)C(=O)C3=CC=C(Cl)C(Cl)=C3
InChI
InChIKey=JUBNVWGVNWIXMB-IAGOWNOFSA-N
InChI=1S/C18H24Cl2N2O/c1-21(18(23)13-8-9-14(19)15(20)12-13)16-6-2-3-7-17(16)22-10-4-5-11-22/h8-9,12,16-17H,2-7,10-11H2,1H3/t16-,17-/m1/s1
U-54494A is a unique and selective anticonvulsant agent acting by a Ca(2+)-related mechanism possibly through a subclass of kappa receptors. Voltage- and use-dependent block of the Na and K channels by U-54494A may be an important pharmacological basis for its anticonvulsant action. U-54494A, a racemic mixture of two enantiomers, is being developed and pre-clinically tested as an anticonvulsant drug candidate.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3614 |
|||
Target ID: Voltage-dependent sodium channels (mice) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1309869 |
72.0 µM [IC50] | ||
Target ID: Voltage-gated potassium channels (mice) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1403785 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Two metabolites of anticonvulsant U-54494A: their anticonvulsant activity and interaction with sodium channel. | 1993 Mar 19 |
|
The effects of anticonvulsant agents on 4-aminopyridine induced epileptiform activity in rat hippocampus in vitro. | 1995 Feb |
|
Pharmacokinetics of the individual enantiomers of cis-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]-benzamide monohydrochloride (U-54494A) in the dog. | 1996 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8229743
Mice Intraperitoneal: ED50 = 28 mg/kg (15 min) and 38 mg/kg (30 min)
Mice Oral: ED50 = 61 mg/kg (30 min) and 65 mg/kg (60 min)
Mice Subcutaneous: ED50 = 24 mg/kg (15 min)
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8098655
At a concentration of 100 microM, U-54494A significantly reduced the availability of cytosolic free calcium (Ca2+) in depolarized MF-enriched synaptosomes by 30% and inhibited the K(+)-evoked release of endogenous glutamate by 85%.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
I3NE36R0XJ
Created by
admin on Fri Dec 15 19:42:27 GMT 2023 , Edited by admin on Fri Dec 15 19:42:27 GMT 2023
|
PRIMARY | |||
|
122015
Created by
admin on Fri Dec 15 19:42:27 GMT 2023 , Edited by admin on Fri Dec 15 19:42:27 GMT 2023
|
PRIMARY | |||
|
DTXSID60918854
Created by
admin on Fri Dec 15 19:42:27 GMT 2023 , Edited by admin on Fri Dec 15 19:42:27 GMT 2023
|
PRIMARY | |||
|
92953-41-8
Created by
admin on Fri Dec 15 19:42:27 GMT 2023 , Edited by admin on Fri Dec 15 19:42:27 GMT 2023
|
PRIMARY |
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD